<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026675</url>
  </required_header>
  <id_info>
    <org_study_id>07-027</org_study_id>
    <secondary_id>OG-3-08-2622-JA</secondary_id>
    <nct_id>NCT01026675</nct_id>
  </id_info>
  <brief_title>Early Screening for Gestational Diabetes Mellitus</brief_title>
  <acronym>DG2</acronym>
  <official_title>Early Screening for Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The working hypothesis of this proposal is that screening for gestational diabetes mellitus
      as early as the 1st trimester is efficient for detecting the forthcoming presence or absence
      of gestational diabetes mellitus. The investigators long-term goal is the prevention of
      gestational diabetes mellitus onset i.e. the prevention of progression to gestational
      diabetes mellitus, in order to enable delivery of appropriate counselling, diagnostics and
      treatment for pregnant women, as well as to improve pregnancy outcomes. Therefore, robust 1st
      trimester screening criteria is needed.

      The overall objective of this proposal is to determine an accurate and valid 1st trimester 1h
      post 50g oral glucose challenge test plasma glucose cut-off value that is predictive of
      gestational diabetes mellitus onset.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oral glucose challenge test plasma glucose value</measure>
    <time_frame>6-13 weeks</time_frame>
    <description>the sensitivity, specificity, positive and negative predictive values of oral glucose challenge test plasma glucose &gt;= 7.8 mmol/L during the 1st trimester (6-13 weeks of gestation), as compared with fasting 75g glucose oral glucose tolerance test performed between the 24th and 28th weeks of gestation (the Canadian Diabetes Association - CDA gold standard).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oral glucose challenge test plasma glucose cut-off value</measure>
    <time_frame>6-13 weeks</time_frame>
    <description>1st trimester 1h post 50g oral glucose challenge test plasma glucose cut-off value that offers optimal sensibility and specificity compared to the 75g oral glucose tolerance test performed between the 24th and 28th weeks of gestation, based on the ROC curve and the maximal likelihood ratio for a positive test.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1442</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pregnant women 6-13 weeks</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>50 g oral glucose challenge test - 75 g oral glucose tolerance test</intervention_name>
    <description>50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.</description>
    <arm_group_label>Pregnant women 6-13 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 yrs

          -  Gestational age between 6 and 13 weeks from last menstrual period,

          -  Alcohol &lt; 2 drinks/day

          -  Not involved in regular high intensity physical activity

          -  Singleton pregnancy

          -  Otherwise good health status.

        Exclusion Criteria:

          -  Type 1 or type 2 diabetes

          -  Taking drugs interfering with glucose metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Ardilouze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche clinique Étienne-Le Bel du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Jean-Luc Ardilouze</investigator_full_name>
    <investigator_title>Endocrinologist, researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

